Annual CFF
-$6.55 M
-$6.48 M-9392.75%
December 31, 2023
Summary
- As of February 20, 2025, XLO annual cash flow from financing activities is -$6.55 million, with the most recent change of -$6.48 million (-9392.75%) on December 31, 2023.
- During the last 3 years, XLO annual CFF has fallen by -$16.58 million (-165.31%).
- XLO annual CFF is now -102.51% below its all-time high of $260.67 million, reached on December 31, 2021.
Performance
XLO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$3000.00
-$20.05 M-100.01%
September 30, 2024
Summary
- As of February 20, 2025, XLO quarterly cash flow from financing activities is -$3000.00, with the most recent change of -$20.05 million (-100.01%) on September 30, 2024.
- Over the past year, XLO quarterly CFF has increased by +$1.63 million (+99.82%).
- XLO quarterly CFF is now -100.00% below its all-time high of $144.89 million, reached on March 31, 2021.
Performance
XLO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$19.36 M
+$2.23 M+13.04%
September 30, 2024
Summary
- As of February 20, 2025, XLO TTM cash flow from financing activities is $19.36 million, with the most recent change of +$2.23 million (+13.04%) on September 30, 2024.
- Over the past year, XLO TTM CFF has increased by +$25.91 million (+395.57%).
- XLO TTM CFF is now -92.57% below its all-time high of $260.67 million, reached on December 31, 2021.
Performance
XLO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XLO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9392.8% | +99.8% | +395.6% |
| 3 y3 years | -165.3% | +99.8% | +395.6% |
| 5 y5 years | - | +99.8% | +395.6% |
XLO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -102.5% | at low | -100.0% | +99.9% | -92.6% | +395.6% |
| 5 y | 5-year | -102.5% | at low | -100.0% | +99.9% | -92.6% | +395.6% |
| alltime | all time | -102.5% | at low | -100.0% | +99.9% | -92.6% | +395.6% |
Xilio Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3000.00(-100.0%) | $19.36 M(+13.0%) |
| Jun 2024 | - | $20.04 M(+2000.9%) | $17.13 M(-538.3%) |
| Mar 2024 | - | $954.00 K(-158.4%) | -$3.91 M(-40.3%) |
| Dec 2023 | -$6.55 M(+9392.8%) | -$1.63 M(-26.9%) | -$6.55 M(+32.7%) |
| Sep 2023 | - | -$2.24 M(+125.4%) | -$4.94 M(+81.3%) |
| Jun 2023 | - | -$992.00 K(-41.2%) | -$2.72 M(+55.4%) |
| Mar 2023 | - | -$1.69 M(+7938.1%) | -$1.75 M(+2439.1%) |
| Dec 2022 | -$69.00 K | -$21.00 K(-4.5%) | -$69.00 K(-100.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$22.00 K(+4.8%) | $115.78 M(-0.3%) |
| Jun 2022 | - | -$21.00 K(+320.0%) | $116.10 M(+0.3%) |
| Mar 2022 | - | -$5000.00(-100.0%) | $115.77 M(-55.6%) |
| Dec 2021 | $260.67 M(+2499.1%) | $115.83 M(>+9900.0%) | $260.67 M(+80.0%) |
| Sep 2021 | - | $301.00 K(-186.2%) | $144.84 M(+0.2%) |
| Jun 2021 | - | -$349.00 K(-100.2%) | $144.54 M(-0.2%) |
| Mar 2021 | - | $144.89 M | $144.89 M |
| Dec 2020 | $10.03 M(-83.3%) | - | - |
| Dec 2019 | $60.02 M | - | - |
FAQ
- What is Xilio Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Xilio Therapeutics?
- What is Xilio Therapeutics annual CFF year-on-year change?
- What is Xilio Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Xilio Therapeutics?
- What is Xilio Therapeutics quarterly CFF year-on-year change?
- What is Xilio Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Xilio Therapeutics?
- What is Xilio Therapeutics TTM CFF year-on-year change?
What is Xilio Therapeutics annual cash flow from financing activities?
The current annual CFF of XLO is -$6.55 M
What is the all time high annual CFF for Xilio Therapeutics?
Xilio Therapeutics all-time high annual cash flow from financing activities is $260.67 M
What is Xilio Therapeutics annual CFF year-on-year change?
Over the past year, XLO annual cash flow from financing activities has changed by -$6.48 M (-9392.75%)
What is Xilio Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of XLO is -$3000.00
What is the all time high quarterly CFF for Xilio Therapeutics?
Xilio Therapeutics all-time high quarterly cash flow from financing activities is $144.89 M
What is Xilio Therapeutics quarterly CFF year-on-year change?
Over the past year, XLO quarterly cash flow from financing activities has changed by +$1.63 M (+99.82%)
What is Xilio Therapeutics TTM cash flow from financing activities?
The current TTM CFF of XLO is $19.36 M
What is the all time high TTM CFF for Xilio Therapeutics?
Xilio Therapeutics all-time high TTM cash flow from financing activities is $260.67 M
What is Xilio Therapeutics TTM CFF year-on-year change?
Over the past year, XLO TTM cash flow from financing activities has changed by +$25.91 M (+395.57%)